Acute myeloid leukemia prognosis
Fact-checked by The prognosis of acute myeloid leukemia (AML) is different for each individual and can change over time depending on how the blood cancer evolves and responds to treatment. There is no way to predict the disease course with certainty, but factors such as age, overall health, treatment responses, and AML subtype can help doctors estimate the outlook.
Understanding AML survival statistics
There are various ways to estimate cancer survival. In U.S. databases, AML survival rates are expressed as relative survival, an estimate of the proportion of people who will survive AML for a specified period after diagnosis, excluding deaths from other causes.
The number is obtained by dividing the survival of people with AML by the expected survival in a similar group from the general population over a given period. For example, a 75% relative one-year survival rate would mean that a person is 75% as likely to survive for one year as someone of the same age and sex in the general population.
It is important to know that the latest statistics are not always fully up to date, so they may not reflect recent advances in treatment that could improve survival. Moreover, not all sources use relative survival statistics — there are many other ways to express these numbers.
For these reasons, it is important to always consult with a healthcare provider who can help patients understand what the data might mean for their AML life expectancy.
Does AML affect life expectancy?
AML can affect life expectancy, although this varies widely between individuals.
In the U.S., the five-year relative survival rate from 2016 to 2022 was 33.4%, indicating that about one-third of people with AML were expected to survive their cancer for at least five years after diagnosis. It was estimated that about 11,500 people in the U.S. would die from AML in 2026. AML survival rates in the country have been steadily improving in recent decades.
Global AML survival statistics are more sparse, and data can vary depending on a region’s healthcare system and treatment access. Trends in other high-income regions, including countries in Europe, are similar to those seen in the U.S.
Still, these survival numbers are general estimates across all people with AML. There are many potential factors affecting AML survival in an individual case.
Scroll horizontally to view all columns -->
| Risk Factor | Why it matters |
|---|---|
| Age | Older people tend to have a poorer AML prognosis. |
| Overall health | Health may affect treatment options and responses. |
| AML subtype | Certain genetic factors tend to be linked to a worse outlook. |
| Treatment responses | A stronger or faster response typically predicts better survival. |
| Disease status at diagnosis | People with higher white blood cell counts at diagnosis tend to have poorer outcomes. |
| Medical history | AML that developed from another blood disease or is related to a previous cancer therapy tends to be more difficult to treat. |
| Complications | Serious infections or leukemia cell infiltration into the nervous system can contribute to a poorer prognosis. |
After an AML diagnosis, doctors can use these factors to estimate a person’s AML prognosis, but this isn’t always precise. It can also change over time as a person’s cancer evolves or their health status changes.
The role of age and overall health
AML prognosis by age varies substantially. Older adults are less likely to achieve complete AML remission — when the signs of cancer in standard tests are gone after treatment — and generally have poorer survival outcomes than younger patients. Between 2000 and 2022, the five-year relative survival statistics in the U.S. by age were:
- younger than age 15: 67%
- ages 15 to 39: 60%
- ages 40 to 64: 38%
- ages 65 to 74: 15%
- ages 75 and older: 4%
The specific numbers may vary by geographical region, time frame, and other factors, but data generally show a downward trend in survival with increasing age.
This may be in part because older people are more likely to have genetic features associated with a worse prognosis. They are also more likely to have other medical conditions that compromise their overall health and make it difficult to complete rigorous courses of AML treatment.
Age is not the only factor that determines a person’s overall health (fitness). Younger people with medical conditions that affect their fitness level may also have a worse AML outlook.
How AML subtype affects prognosis
There are many subtypes of AML, typically classified by their defining genetic features. Certain genetic changes are associated with a more aggressive cancer, including lower chances of AML remission and worse long-term outcomes. The European Leukemia Network (ELN) has published guidelines about how doctors can use genetic factors to predict the disease course.
This ELN risk classification system sorts patients into AML risk groups with favorable, intermediate, or adverse genetic signatures. It is based on the assumption that all patients will receive high-intensity chemotherapy. There is a separate risk stratification system for people who will receive lower-intensity treatments.
While these systems can be used as a prognostic tool at the time of diagnosis, AML genetic risk factors alone can’t accurately predict an individual’s disease trajectory — treatment and other factors play a role. Researchers are developing treatments that target specific genetic abnormalities, which could affect how genetic factors influence AML outlook in the future.
How treatment affects outlook
Access to prompt and appropriate treatment is a major factor influencing the outlook for AML. Without any treatment, AML is fatal within weeks to months.
The initial response to treatment affects long-term outlook. People who achieve complete remission more quickly generally have a better AML prognosis, while a longer time to achieve remission or a failure to achieve it at all can mean the disease will be more difficult to treat.
The very small number of cancer cells that can remain even after complete remission is achieved — called measurable residual disease (MRD) — can also affect prognosis. The absence of MRD is usually linked to better long-term outcomes.
After initial remission, many people with AML at some point experience cancer recurrence, called a relapse. Relapsed AML tends to have a poorer outlook.
Questions to ask your care team about prognosis
Doctors can provide the most accurate information about prognosis in a given situation, although there will always be uncertainty about potential outcomes. People with AML may want to ask their care teams about:
- the risk classification of their AML subtype
- how new test results may affect their prognosis over time
- other factors that may influence their prognosis
- mental health resources or support services for coping with uncertainty
Open communication about the individualized and evolving nature of AML outlook can help doctors, caregivers, and patients make informed decisions throughout the diagnosis and treatment process.
Rare Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
